AR077168A2 - Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida - Google Patents

Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida

Info

Publication number
AR077168A2
AR077168A2 ARP100100845A ARP100100845A AR077168A2 AR 077168 A2 AR077168 A2 AR 077168A2 AR P100100845 A ARP100100845 A AR P100100845A AR P100100845 A ARP100100845 A AR P100100845A AR 077168 A2 AR077168 A2 AR 077168A2
Authority
AR
Argentina
Prior art keywords
particles
organic compound
particles according
storage
organic compounds
Prior art date
Application number
ARP100100845A
Other languages
English (en)
Inventor
Juan Angeles Uribe
Gyves Aurelio De
Abraham Gomez
Original Assignee
John Claude Savoir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21853984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077168(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by John Claude Savoir filed Critical John Claude Savoir
Publication of AR077168A2 publication Critical patent/AR077168A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Una pluralidad de partículas estables durante el almacenamiento de un tamano y forma definitivos, que consisten esencialmente de un compuesto orgánico alotropico de estructura cristalina uniforme, dicho compuesto orgánico retiene dicha estructura cristalina, y dichas partículas que retienen dichos tamanos, y forma durante el almacenamiento en el medio acuoso durante por lo menos un mes y método para realizar la cristalizacion en estado solido. Reivindicacion 2: Las partículas de acuerdo con reivindicacion 1, caracterizadas porque las partículas son microesferas. Reivindicacion 3: Las partículas de acuerdo con la reivindicacion 2, caracterizadas porque las partículas son microesferas de diámetro que oscila entre 1 y 1.000 micrones. Reivindicacion 4: Las partículas de acuerdo con alguna de las reivindicaciones 1 a 3, caracterizadas porque la forma cristalina deseada de dicho compuesto orgánico alotropico es un hidrato. Reivindicacion 5: Las partículas de acuerdo con alguna de las reivindicaciones 1 a 4, caracterizadas porque dicho compuesto orgánico alotropico es un esteroide o un esterol. Reivindicacion 7: Las partículas de acuerdo con alguna de las reivindicaciones 1 a 4, caracterizadas porque dicho compuesto orgánico alotropico es astemizol, cisaprida u oxatomida.
ARP100100845A 1998-02-25 2010-03-17 Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida AR077168A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/030,388 US6287693B1 (en) 1998-02-25 1998-02-25 Stable shaped particles of crystalline organic compounds

Publications (1)

Publication Number Publication Date
AR077168A2 true AR077168A2 (es) 2011-08-10

Family

ID=21853984

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990100728A AR018107A1 (es) 1998-02-25 1999-02-23 Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo
ARP100100845A AR077168A2 (es) 1998-02-25 2010-03-17 Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida
ARP100100844A AR077167A2 (es) 1998-02-25 2010-03-17 Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990100728A AR018107A1 (es) 1998-02-25 1999-02-23 Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100100844A AR077167A2 (es) 1998-02-25 2010-03-17 Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos

Country Status (35)

Country Link
US (7) US6287693B1 (es)
EP (4) EP1056444B1 (es)
JP (2) JP4885357B2 (es)
KR (1) KR100726315B1 (es)
CN (2) CN1146407C (es)
AR (3) AR018107A1 (es)
AT (2) ATE427102T1 (es)
AU (1) AU747779B2 (es)
BR (1) BR9908156A (es)
CA (1) CA2319176C (es)
CL (1) CL2010001333A1 (es)
CY (1) CY1118522T1 (es)
CZ (1) CZ301042B6 (es)
DE (2) DE69940684D1 (es)
DK (3) DK1056444T3 (es)
EE (1) EE05019B1 (es)
ES (3) ES2609284T3 (es)
HK (2) HK1036017A1 (es)
HU (1) HUP0101271A3 (es)
ID (1) ID26523A (es)
IL (2) IL137970A0 (es)
MY (1) MY138375A (es)
NO (1) NO331804B1 (es)
NZ (1) NZ505987A (es)
PE (1) PE20000393A1 (es)
PL (1) PL196369B1 (es)
PT (1) PT2085075T (es)
RU (1) RU2225708C2 (es)
SA (1) SA99200098B1 (es)
TR (1) TR200002462T2 (es)
TW (1) TWI256308B (es)
UA (1) UA73470C2 (es)
UY (1) UY25404A1 (es)
WO (1) WO1999043304A1 (es)
ZA (1) ZA991058B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
NZ536497A (en) * 2002-05-16 2006-08-31 Tibotec Pharm Ltd Pseudopolymorphic forms of a HIV protease inhibitor and their use as a medicament
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
JP4956185B2 (ja) * 2003-06-13 2012-06-20 スケンディ ファイナンス リミテッド 避妊及びホルモン補充療法用の調合製剤
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
WO2005009375A2 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
CN1889932A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 制备药用多颗粒的方法
ME02661B (me) 2004-02-23 2017-06-20 Euro Celtique Sa Opioidni transdermalni preparat otporan na zloupotrebu
RU2008100543A (ru) * 2005-06-17 2009-07-27 БАСФ Акциенгезельшафт (DE) Способ получения усилителей эффекта отбеливания
WO2009120889A2 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
EP2272519A4 (en) * 2008-04-14 2011-04-27 Posi Visionary Solutions Llp METHOD AND PHARMACEUTICAL COMPOSITION FOR ACHIEVING THE PLASMA PROGESTERONE MIRRORS NECESSARY FOR VARIOUS THERAPEUTIC INDICATIONS
FR2939326B1 (fr) * 2008-12-10 2011-04-01 Univ Joseph Fourier Procede et dispositif de controle d'une cristallisation.
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP2548879B1 (en) * 2010-03-19 2015-12-09 Daiichi Sankyo Company, Limited Crystal of diamine derivative and method of producing same
KR101314126B1 (ko) 2011-03-11 2013-10-04 서울대학교산학협력단 다면체 형상의 약물 전달 시스템
US9351924B2 (en) 2011-03-11 2016-05-31 Snu R&Db Foundation Drug delivery system including laminated structure
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CN106414442B (zh) 2014-04-23 2019-03-15 因赛特公司 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
PE20190623A1 (es) 2016-06-20 2019-04-26 Incyte Corp Formas solidas cristalinas de un inhibidor de bet
PL236889B1 (pl) * 2017-10-03 2021-02-22 Univ Warszawski Medyczny Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447362A (en) 1945-11-01 1948-08-17 Rca Corp Production of crystals
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US4230621A (en) * 1978-05-01 1980-10-28 E. R. Squibb & Sons, Inc. Steroid derivatives and their use in radioimmunoassays
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
DE3049196A1 (de) 1980-12-24 1982-07-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von granulaten aus organischen in form einer schmelze vorliegenden stoffen
US4447426A (en) * 1982-01-18 1984-05-08 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
JPS58143832A (ja) 1982-02-22 1983-08-26 Yoshiaki Kawashima 結晶性化学物質の球状化再結晶法
DE3213025C2 (de) 1982-04-02 1997-06-12 Fischer Karl Ind Gmbh Verfahren zur Nachkondensation von Polykondensaten
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
JPH0714625B2 (ja) 1987-03-30 1995-02-22 呉羽化学工業株式会社 高結晶化ポリアリ−レンチオエ−テル成形物
US4897307A (en) 1987-08-11 1990-01-30 The Dow Chemical Company Process for the solvent-induced crystallization of amorphous poly(etheretherketone)-type polymers and the article formed thereby
CA1305579C (en) 1987-09-28 1992-07-21 Shinsuke Fukuoka Method for producing a crystallized aromatic polycarbonate, and a crystallized aromatic polycarbonate obtained thereby
US4919899A (en) 1988-02-29 1990-04-24 Herrmann Frederick T Crystal growth apparatus
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
IT1230566B (it) * 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5360478A (en) 1989-10-16 1994-11-01 Phasex Corporation Gas anti-solvent recrystallization process
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
JPH04305226A (ja) 1991-01-25 1992-10-28 Senichi Masuda ガス中窒素酸化物の低減方法
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5391810A (en) 1991-05-23 1995-02-21 Ajinomoto Co., Inc. Method of crystallizing α-L-aspartyl-L-phenylalanine methyl ester
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
DE4218929C1 (es) 1992-06-10 1993-09-09 Deutsche Bundesbahn, Vertreten Durch Das Bundesbahn-Zentralamt Minden (Westf.), 4950 Minden, De
US5290913A (en) 1992-10-08 1994-03-01 Carrier Vibrating Equipment, Inc. Method and apparatus for the heat treatment of material
US5558678A (en) 1992-11-13 1996-09-24 Karl Fischer Industrieanlagen Gmbh Process and apparatus for continuous crystallization of plastic granules
US5686092A (en) 1992-11-24 1997-11-11 Alkermes Controlled Therapeutics Inc. Ii Growth promoters for animals
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US5409605A (en) * 1993-08-05 1995-04-25 Chemical Lime Company Apparatus and method for treating waste sludge
JPH0757558A (ja) * 1993-08-09 1995-03-03 Showa Electric Wire & Cable Co Ltd 耐熱絶縁電線
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5849651A (en) * 1995-06-01 1998-12-15 Kabushiki Kaisha Toshiba Reversible thermal recording medium
JPH0957558A (ja) * 1995-08-18 1997-03-04 Nabeya Iron & Tool Works Ltd スライド装置
JPH09227558A (ja) * 1996-02-28 1997-09-02 Fujisawa Pharmaceut Co Ltd チアゾール化合物の安定な結晶およびその製造方法
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
JP2000143832A (ja) 1998-11-10 2000-05-26 Toppan Printing Co Ltd 高剛性を有するフィルムまたはシート

Also Published As

Publication number Publication date
NO20004241D0 (no) 2000-08-24
CA2319176A1 (en) 1999-09-02
TR200002462T2 (tr) 2000-11-21
US20020168395A1 (en) 2002-11-14
EP2319497A1 (en) 2011-05-11
ATE427102T1 (de) 2009-04-15
NO331804B1 (no) 2012-04-10
US6737081B2 (en) 2004-05-18
CY1118522T1 (el) 2017-07-12
ES2324366T3 (es) 2009-08-05
JP4885357B2 (ja) 2012-02-29
PE20000393A1 (es) 2000-05-04
MY138375A (en) 2009-05-29
ES2609284T3 (es) 2017-04-19
US20030147964A1 (en) 2003-08-07
PL196369B1 (pl) 2007-12-31
IL137970A (en) 2006-10-05
CA2319176C (en) 2007-09-11
DE69934099D1 (de) 2007-01-04
IL137970A0 (en) 2001-10-31
BR9908156A (pt) 2000-10-31
EP1772141A1 (en) 2007-04-11
NZ505987A (en) 2003-07-25
CN1291887A (zh) 2001-04-18
CN100528140C (zh) 2009-08-19
US20040166164A1 (en) 2004-08-26
TWI256308B (en) 2006-06-11
ATE345779T1 (de) 2006-12-15
UY25404A1 (es) 1999-05-14
HUP0101271A3 (en) 2002-10-28
EE200000492A (et) 2002-02-15
PL343170A1 (en) 2001-07-30
KR20010034540A (ko) 2001-04-25
US6287693B1 (en) 2001-09-11
JP2002504507A (ja) 2002-02-12
JP2011241220A (ja) 2011-12-01
RU2225708C2 (ru) 2004-03-20
HK1036017A1 (en) 2001-12-21
US6528094B1 (en) 2003-03-04
AU747779B2 (en) 2002-05-23
US6537580B1 (en) 2003-03-25
DK1772141T3 (da) 2009-07-20
HK1155384A1 (en) 2012-05-18
US7427413B2 (en) 2008-09-23
EE05019B1 (et) 2008-06-16
EP1056444A1 (en) 2000-12-06
EP2085075B1 (en) 2016-09-28
WO1999043304A1 (en) 1999-09-02
AU2293699A (en) 1999-09-15
DK1056444T3 (da) 2007-03-12
PT2085075T (pt) 2017-01-04
US6663895B2 (en) 2003-12-16
AR018107A1 (es) 2001-10-31
CZ301042B6 (cs) 2009-10-21
ES2275334T3 (es) 2007-06-01
EP2319497B1 (en) 2012-08-22
DE69934099T2 (de) 2007-06-21
CL2010001333A1 (es) 2011-04-25
EP1772141B1 (en) 2009-04-01
DE69940684D1 (de) 2009-05-14
CZ20003047A3 (cs) 2000-11-15
NO20004241L (no) 2000-08-24
AR077167A2 (es) 2011-08-10
ID26523A (id) 2001-01-11
UA73470C2 (uk) 2005-08-15
CN1146407C (zh) 2004-04-21
SA99200098B1 (ar) 2006-04-26
EP2085075A1 (en) 2009-08-05
US20030191101A1 (en) 2003-10-09
DK2085075T3 (en) 2017-01-23
KR100726315B1 (ko) 2007-06-11
CN1524608A (zh) 2004-09-01
EP1056444B1 (en) 2006-11-22
HUP0101271A2 (hu) 2001-09-28
ZA991058B (en) 1999-08-11
US6638536B2 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
AR077168A2 (es) Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida
CY1117370T1 (el) Φαρμακευτικη παστιλια με βραδεια απελευθερωσης του δραστικου παραγοντα
Zhivotovsky et al. Formation of 50 kbp chromatin fragments in isolated liver nuclei is mediated by protease and endonuclease activation
MX11339A (es) Una suspension acuosa estable con caracteristicas de liberacion retardada de carbamacepina y procedimiento para su preparacion
AR240958A2 (es) Una composicion detergente acuosa que comrende un gel".
ES2118677T1 (es) Una composicion que comprende un agente activo disuelto en un vehiculo vitrificante y un procedimiento para su preparacion.
EE03838B1 (et) Sisselõikuv kruvi, eriti betoonikruvi, ja selle kasutamine
ES2062563T5 (es) Procedimiento para preparar un solido hidrofobo o aerofilo dispersable en agua.
AU2002246647A1 (en) Apparatus and method for the automated preparation of biopolymer crystals with high output
ES524518A0 (es) Un procedimiento para preparar un agente anti-inflamatorio
BR9605886A (pt) Processo para produção de composições de substância ativa na forma de uma solução sólida da substância atina em uma matriz de polímero e composição de substância ativa
CO5180561A1 (es) Metodo para reducir la deposicion de una sal mineral de una solucion acuosa supersaturada sobre una superficie de contacto con la solucion acuosa supersaturada
MX9201141A (es) Ciclosporinas cristalinas, procedimiento para su produccion y composicion farmaceutica que las contiene.
FR2811319B1 (fr) Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
IT1235358B (it) Derivati 17beta-oh 19-nor steroidei sostituiti in 17alfa, procedimento di preparazione, loro impiego come medicamenti e composizioni farmaceutiche che li compongono
MX172804B (es) Composicion de cebo para insectos en forma de tableta y procedimiento para su preparacion
ES2148419T3 (es) Conjunto de freno de tambor.
ES2031232T3 (es) Dispositivo para quitar tapones generalmente fungiformes de botellas.
BR8405020A (pt) Processo para preparacao de derivados de ciclo-hexenol,e,composicoes herbicidas,contendo tais derivados
PT101554A (pt) Processo para a cristalizacao de iopamidol utilizando um butanol como solvente, iopamidol cristalino assim obtido e agentes de contraste radiograficos que o contem
DE60008960D1 (de) II-VI Verbindungshalbleiterkristalle vom Type-P, Verfahren zu ihrer Züchtung und ihre Verwendung in Halbleitereinrichtungen
MX172610B (es) Catalizador de zeolita y procedimiento para utilizar este catalizador
DE3888527D1 (de) Biologisch abbaubare und resorbierbare chirurgische materialien und verfahren zu deren herstellung.
BR8700449A (pt) Composicao interligante retardada contendo complexos de titanio organico,processo para a preparacao de uma solucao de gel,e processo de fratura de formacao subterranea penerada por um poco
BR8900467A (pt) Processo e composicao de liga para fabricar eixos

Legal Events

Date Code Title Description
FC Refusal